苏珊·B·安东尼反堕胎组织在提名获确认前,曾要求确保结束米非司酮的邮购渠道
作者:兰登·米恩 / 福克斯新闻 发布时间:2026年11月20日 美国东部时间凌晨12:32
反堕胎团体称,因未就堕胎药政策作出承诺,导致其反对奥弗顿的FDA提名失败
苏珊·B·安东尼反堕胎组织法律策略高级副总裁埃里克·巴普蒂斯特解释了该组织为何反对海蒂·奥弗顿的FDA提名——前提是特朗普政府未作出承诺,以恢复堕胎药的当面配发要求,并解决该机构对米非司酮的安全研究存在的问题。
新功能:现在可收听福克斯新闻的文章!
一家领先的反堕胎团体表示,他们反对推进海蒂·奥弗顿领导美国食品药品监督管理局(FDA)的提名,原因是特朗普政府在堕胎药政策上未作出承诺。白宫本周因她在参议院的支持情况存疑,撤回了对她的提名。
在接受福克斯新闻数字频道采访时,苏珊·B·安东尼反堕胎组织法律策略高级副总裁埃里克·巴普蒂斯特表示,该组织曾要求参议院推迟奥弗顿的确认程序,直至该组织从政府获得关于堕胎药政策两方面的“明确承诺”。
巴普蒂斯特称,该组织希望下一任FDA提名人承诺结束拜登政府授权的堕胎药邮购渠道,并改变该机构对这些药物安全性的研究方式。
“如今我国的堕胎数量比最高法院推翻《罗诉韦德案》裁决之前还要多,”巴普蒂斯特说,“这正是因为拜登政府领导下的FDA授权了堕胎药的邮购渠道。我们看到,在反堕胎州,每有15000多例堕胎药及堕胎手术发生。当这项全国性政策实施时,这些州根本无法有效执行相关法律。”
白宫在参议院小组投票前夕撤回特朗普的FDA提名者海蒂·奥弗顿
白宫称海蒂·奥弗顿在国会参众两院缺乏足够票数,因此撤回了她的提名。(Bonnie Cash/UPI/Bloomberg via Getty Images)
“在拜登政府的政策下,任何人都可以在网上获取这些药物,并通过邮寄接收,”他继续说道,“我说的‘任何人’,我们每周都能看到新闻报道,有男子或其他掠夺者通过这些药物,胁迫或毒害女性违背自身意愿服用。除非改变这项政策,否则任何孕妇都无法免受这些药物的伤害。我想问问本届政府:还要有多少女性因堕胎药被毒害或胁迫,你们才会对这种药物采取行动?”
在拜登政府时期,FDA取消了米非司酮的当面配发要求,允许获得认证的开处方者无需当面就诊即可开出处方,并由获得认证的药房通过邮寄方式配发。
针对该组织的第二点担忧,巴普蒂斯特表示,FDA需要开展一项新研究,以证明米非司酮的安全性(或不安全之处)。
“问题在于这项研究存在重大缺陷,”他说,“它几乎是为了失败而设计的,无法推动药品方案的未来调整。我们曾要求提供更可靠的数据,因为目前缺少大量信息,包括该机构方法的透明度,以及邀请过去几十年研究过这种药物的外部专家参与。”
“这应该是两党一致的事情。每个人都应该支持更好的数据、更多透明度,以及能为从未开展过此类研究的机构提供信息的外部专家,”他补充道。
多个反堕胎团体及共和党议员已敦促特朗普政府完成FDA对米非司酮的安全审查,并考虑恢复保护措施,而部分团体则呼吁将该药物从市场上移除。
FDA表示,审查仍在进行中,研究结果预计于2026年12月公布,最终报告预计于2027年3月发布。
白宫本周早些时候撤回了奥弗顿领导FDA的提名,时间恰好是参议院委员会投票的前一天。唐纳德·特朗普总统于8月提名了作为医生兼白宫顾问的奥弗顿,接替5月辞职的马蒂·马卡里。
马卡里离任后,凯尔·迪亚曼塔斯一直以代理身份领导该机构。
称堕胎药差点致其死亡的女子敦促RFK Jr.采取行动,该团体要求打击邮购堕胎药
海蒂·奥弗顿曾在白宫与唐纳德·特朗普总统一同出席,当时他签署了一项行政命令,呼吁修改儿童疫苗建议。(Anna Moneymaker/Getty Images)
奥弗顿此前还曾担任保守派智库“美国第一政策研究所”的副主席兼首席政策官,她在2023年的一份政策简报中批评了堕胎药获取渠道的扩大。
白宫称奥弗顿在国会参众两院缺乏足够票数,因此撤回了她的提名,不过参议院卫生委员会主席比尔·卡西迪参议员认为,他相信她本可以获得确认。
“白宫放弃了奥弗顿博士可行的确认路径。白宫称这是因为她没有足够票数通过确认。这很奇怪,因为我当时正与议员们进行富有成效的对话,”路易斯安那州共和党参议员卡西迪在社交媒体平台X上写道,“我相信她本可以在委员会和参议院全体会议上获得通过所需的票数。”
巴普蒂斯特表示,他不知道白宫是担心反堕胎派的选票还是其他群体,但他认为卡西迪“正在与政府取得进展,以确保我们所寻求的承诺,并要求参议院监督政府落实这些承诺”。
卡西迪曾批评奥弗顿支持特朗普调整儿童疫苗接种时间表的决定,但这位参议员表示,在她承诺“遵循科学”后,他已确信她是该职位的合适人选。她曾在白宫与特朗普一同出席,当时总统签署了一项行政命令,呼吁修改儿童疫苗建议,包括建议一旦国内有单独剂型可用,就分别接种麻疹、腮腺炎和风疹疫苗。
卡西迪在9月的听证会上表示,特朗普提出联合疫苗可能“极具杀伤力”的说法没有科学依据,并警告这一言论可能会阻碍疫苗接种。
“是的,参议员,麻腮风疫苗(MMR)是安全有效的,”奥弗顿对卡西迪说。
当被问及如果特朗普要求她无视FDA的安全标准,她会怎么做时,奥弗顿表示,她会向总统提供最佳建议,并遵循审查个别产品的法律要求。
新罕布什尔州民主党参议员玛吉·哈桑直接询问奥弗顿,特朗普的说法是否错误。奥弗顿重申该疫苗安全有效,并称之为麻疹疫情期间可获得的最佳工具。马萨诸塞州民主党参议员埃德·马基质疑她为何在白宫没有纠正特朗普的说法。
“我们为什么要指望你作为FDA commissioner站出来反对总统?”马基问道。
参议院卫生委员会主席比尔·卡西迪参议员表示,他相信海蒂·奥弗顿本可以获确认领导FDA。(Tasos Katopodis/Getty Images)
巴普蒂斯特表示,他希望下一任FDA commissioner是一位“懂科学”且有机构管理经验的人。
“FDA是一个拥有多个利益相关方的大型官僚机构,因此对科学开展方式和药品审批流程的了解,对该职位的任何成功候选人或提名人来说都至关重要,”他说。
但巴普蒂斯特表示,政府无需等待FDA提名人就任,就可以采取该组织希望的堕胎药政策行动。
点击此处下载福克斯新闻应用
“好消息是,并非必须由提名人作出这些承诺。政府可以做到,因为它已承认,凭自身权力可立即采取这些行动,”他认为,“该权力掌握在政府手中。这是政治意愿的问题,而非法律能力的问题。”
“至于修复研究,我认为他们现在就可以做出这些改变,”巴普蒂斯特继续说道,“他们无需等待确认,尤其是当他们声称今年12月就会完成研究的时候。届时可能还没有FDA commissioner,甚至连提名人都没有。因此,他们必须立即修正研究,纠正其错误,以免研究明年完成时已存在致命缺陷。”
福克斯新闻的斯蒂芬妮·普莱斯为本文提供了资料贡献。
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/heidi-overton.png
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/5deac5ae-heidi-overton-trump-oval-office.png
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/overton-cassidy-senate-hearing-fda.png
Pro-life group says Trump admin didn’t give key abortion drug commitments before Overton FDA nomination pulled
Susan B. Anthony Pro-Life America sought guarantees on ending mail-order access to mifepristone before confirmation
By Landon Mion / Fox News Published November 20, 2026 12:32am EST
Pro-life group says lack of abortion drug commitments drove opposition to Overton’s failed FDA bid
Erik Baptist, senior vice president of legal strategy at Susan B. Anthony Pro-Life America, explains why the group opposed Heidi Overton’s FDA confirmation without commitments from the Trump administration to restore in-person dispensing requirements for abortion drugs and address concerns about the agency’s mifepristone safety study.
NEW You can now listen to Fox News articles!
A leading pro-life group said it opposed advancing Heidi Overton’s nomination to lead the Food and Drug Administration without commitments from the Trump administration on abortion drug policy. The White House withdrew her nomination this week amid questions about her support in the Senate.
In an interview with Fox News Digital, Erik Baptist, senior vice president of legal strategy at Susan B. Anthony Pro-Life America, said his group asked the Senate to hold up Overton’s confirmation until it received “firm commitments” from the administration on two fronts regarding abortion drug policy.
Baptist said the group wants the next FDA nominee to commit to ending mail-order access to abortion drugs authorized under the Biden administration and changing how the agency studies the safety of those pills.
“Right now, we’re seeing more abortions in this country than before the Supreme Court’s decision overturning Roe v. Wade,” Baptist said. “That’s precisely because of what the Biden FDA did to authorize mail-order abortion drugs. We’re seeing upwards of 15,000 abortion drugs and abortions occurring in pro-life states. Those states can’t meaningfully enforce their laws while this nationwide policy is in place.”
WHITE HOUSE PULLS TRUMP’S FDA PICK HEIDI OVERTON ON EVE OF SENATE PANEL VOTE
The White House said Heidi Overton lacked the votes on Capitol Hill and pulled her nomination.(Bonnie Cash/UPI/Bloomberg via Getty Images)
“Under the Biden-era policy, anybody can obtain these drugs online and receive them through the mail,” he continued. “When I say anybody, we’ve seen news story after news story every week about men and other predators obtaining these drugs to coerce or poison women into taking them against their will. Until that policy changes, no pregnant woman is safe from these drugs. My question to this administration is: How many more women have to be poisoned or coerced with abortion drugs before you take action on this drug?”
Under the Biden administration, the FDA eliminated the in-person dispensing requirement for mifepristone, allowing it to be prescribed without an in-person visit by certified prescribers and dispensed by certified pharmacies through the mail.
On the group’s second point of concern, Baptist said the FDA needs to conduct a new study to show the safety — or lack thereof — of mifepristone.
“The problem is that the study is significantly flawed,” he said. “It’s almost designed to fail and not lead to future changes to the drug regimen. We have asked for more robust data because significant information is currently lacking, including transparency into the agency’s methodology and an invitation for outside experts who have studied this drug over the last few decades.”
“This is something that should be bipartisan. Everybody should support better data, more transparency and outside experts who can inform an agency that has never conducted such a study before,” he added.
Several pro-life groups and Republican lawmakers have urged the Trump administration to complete the FDA’s safety review of mifepristone and consider reinstating safeguards, while some have called for removing the drug from the market.
The FDA said the review is ongoing, with study results expected in December 2026 and a final report expected by March 2027.
The White House pulled Overton’s nomination to lead the FDA earlier this week, one day before a Senate committee vote. President Donald Trump picked Overton, a physician and White House advisor, in August to succeed Marty Makary, who resigned from the position in May.
Kyle Diamantas has led the agency in an acting capacity since Makary’s departure.
WOMAN WHO SAYS ABORTION PILLS NEARLY KILLED HER URGES RFK JR TO ACT AS GROUP DEMANDS MAIL-ORDER CRACKDOWN
Heidi Overton had appeared alongside President Donald Trump in the Oval Office as he signed an executive order calling for changes to childhood vaccine recommendations.(Anna Moneymaker/Getty Images)
Overton also previously served as vice chair and chief policy officer at the America First Policy Institute, a conservative think tank, where she criticized expanded access to abortion pills in a 2023 policy brief.
The White House said Overton lacked the votes on Capitol Hill and pulled her nomination, although Sen. Bill Cassidy, chair of the Senate health committee, contended that he believed she could have been confirmed.
“The White House abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members,” Cassidy, R-La., wrote on X. “I believe she would have had the votes to pass out of committee and pass the full Senate.”
Baptist said he did not know whether the White House was concerned about pro-life votes or other constituencies but thinks Cassidy “was making progress with the administration to secure the commitments we were seeking and asking the Senate to hold the administration accountable for.”
Cassidy had criticized Overton for supporting Trump’s decision to recommend changes to the childhood vaccine schedule, but the senator said he had been convinced she was right for the job after she committed to “follow the science.” She had appeared alongside Trump in the Oval Office as the president signed an executive order calling for changes to childhood vaccine recommendations, including a recommendation to administer measles, mumps and rubella vaccines separately once individual shots become available domestically.
Cassidy said at a September hearing that there was no scientific evidence for Trump’s suggestion that the combined shot could be “quite lethal” and warned the remark could discourage vaccination.
“Yes, senator, the MMR vaccine is safe and effective,” Overton told Cassidy.
Pressed on what she would do if Trump asked her to disregard the FDA’s safety standards, Overton said she would give the president her best advice and follow the legal requirements for reviewing individual products.
Sen. Maggie Hassan, D-N.H., asked Overton directly whether Trump was wrong. Overton reiterated that the vaccine was safe and effective and called it the best tool available during the measles outbreak. Sen. Ed Markey, D-Mass., questioned why she had not corrected Trump in the Oval Office.
“Why should we expect you to stand up to the president as FDA commissioner?” Markey asked.
Sen. Bill Cassidy, chair of the Senate health committee, said he believed Heidi Overton could have been confirmed to lead the FDA.(Tasos Katopodis/Getty Images)
Baptist said he wants the next FDA commissioner to be somebody who “understands science” and has experience managing an agency.
“The FDA is a very large bureaucracy with multiple constituencies, so understanding how science is conducted and how drugs are approved will be essential to any successful candidate or nominee for the position,” he said.
But, Baptist said, the administration does not have to wait for an FDA nominee to take the position before it can take the action on abortion pill policy that his group desires.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The good news is that it doesn’t have to be the nominee who makes these commitments. The administration can do it because it has admitted that it can take these actions immediately using its own authority,” he argued. “That power is within the administration’s possession. It’s a matter of political will, not legal ability.”
“With regard to fixing the study, I think they can make those changes now,” Baptist continued. “They don’t need to wait for a confirmation, especially when they’re saying they’re going to finish the study in December of this year. We might not have an FDA commissioner at that point, or even a nominee. So they need to fix it immediately and course-correct the study before it’s fatally flawed and completed next year.”
Fox News’Stepheny Price contributed to this report.
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/heidi-overton.png
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/5deac5ae-heidi-overton-trump-oval-office.png
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/overton-cassidy-senate-hearing-fda.png
发表回复